Medical Advocates

Efavirenz
(Sustiva/Strocrin)
 
Journal Citations
 
Animal Studies                  Adolescent/Adult Treatment
Safety                                Economics
General Reports                  
Pharmacogenetics    
Pharmacokinetics       
Drug/Drug Interactions
Viral Dynamics
Resistance
Adverse Events
Drug Monitoring
Diagnostics

Efavirenz Main Page Main New/Newsworthy  Home Page      

Last Update:  March 14, 2018
Perinatal Journal Data are in the Perinatal Data Page. Pediatric Journal Data are in the Pediatric Data Page
 Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader
Animal Studies
 

 

Efavirenz treatment causes arterial stiffening in apolipoprotein E-null mice.
Caulk AW, Soler J, Platt MO, Gleason RL.
J Biomech. 2015 May 21.
Abstract

Efavirenz is a substrate and in turn modulates the expression of the efflux transporter ABCG2/BCRP in the gastrointestinal tract of the rat.
Peroni RN, Di Gennaro SS, Hocht C,  et al
Biochem Pharmacol
. 2011 Jul 23
Abstract

UPLC-MS/MS quantification of nanoformulated ritonavir, indinavir, atazanavir, and efavirenz in mouse serum and tissues.
Huang J, Gautam N, Bathena SP 
JChromatogr B Analyt Technol Biomed Life Sci. 2011 Jul 1
Abstract


Safety
 

  Comparative safety and neuropsychiatric adverse events associated with efavirenz use in first-line antiretroviral therapy: a systematic review and meta-analysis of randomized trials.
Ford N, Shubber Z, Pozniak A, et al
J Acquir Immune Defic Syndr
. 2015 Apr 4.

Abstract

General/Miscellaneous Reports
 

 
FULL-TEXT ARTICLE
Prevalence and correlates of persistent intracellular HIV transcription in individuals on efavirenz versus atazanavir-based regimens: A prospective cohort study.
Pilalas D, Skoura L, Margariti A, et al
PLoS One. 2018 Mar 13;13(3):e0194262.
Peper

Prediction of plasma efavirenz concentrations among HIV-positive patients taking efavirenz-containing combination antiretroviral therapy.
Huang SH, Lin SW, Chang SY, et al;
Sci Rep. 2017 Nov 23;7(1):16187.
Abstract

In vivo genotoxicity evaluation of efavirenz (EFV) and tenofovir disoproxil fumarate (TDF) alone and in their clinical combinations in Drosophila melanogaster.
de Moraes Filho AV, de Jesus Silva Carvalho C,  
Mutat Res
. 2017 Aug;820:31-38. 5
Abstract

Population approach to efavirenz therapy.
Duarte H, Cruz JP, Aniceto N, et al
J Pharm Sci
. 2017 Jun 13.
Abstract

Late efavirenz-induced ataxia and encephalopathy: a case series.
Variava E, Sigauke FR, Norman J,  et al
J Acquir Immune Defic Syndr. 2017 May 17.
Abstract

First results of a phase II trial to assess the efficacy of efavirenz in patients with metastatic androgen-independent prostate cancer.
Houede N, Pulido M, Mourey L, et al
J Clin Oncol. 2012 Feb 10;30(5_suppl):251
Abstract

HIV Non-Nucleoside Reverse Transcriptase Inhibitor Efavirenz Reduces Neural Stem Cell Proliferation In Vitro and In Vivo.
Jin J, Grimmig B, Izzo J, Brown LA, et al
Cell Transplant. 2016 Nov;25(11):1967-1977.
Abstract

Alkynyl Cinchona Catalysts affect Enantioselective Trifluoromethylation for Efavirenz under Metal-Free Conditions.
Okusu S, Hirano K, Yasuda Y, et al   
Org Lett
. 2016 Oct 14.
Abstract

Consequences of a Chronic Exposure of Cultured Brain Astrocytes to the Anti-Retroviral Drug Efavirenz and its Primary Metabolite 8-Hydroxy Efavirenz.
Arend C, Rother A, Stolte S, Dringen R.
Neurochem Res. 2016 Sep 21
Abstract

Inhibition of CYP2B6 Activity by Voriconazole Profiled Using Efavirenz Disposition in Healthy Volunteers.
Desta Z, Metzger IF, Thong N,
Antimicrob Agents Chemother
. 2016 Sep 6.
Abstract

Efavirenz biotransformation as an UP-STREAM EVENT of mood changes in HIV-infected patients.
Grilo NM, Correia MJ, Sequeira C,
Toxicol Lett. 2016 Aug 16.
Abstract

Engineered nanoparticles of Efavirenz using methacrylate co-polymer (Eudragit-E100) and its biological effects in-vivo.
Hari BN, Narayanan N, Dhevendaran K, Ramyadevi D.
Mater Sci Eng C Mater Biol Appl. 2016 Oct 1;67:522-32
Abstract

FULL-TEXT ARTICLE
Cholesterol Hydroxylase CYP46A1: Mapping of the Allosteric Site for Efavirenz, a Drug that Stimulates Enzyme Activity.
Anderson KW, Mast N, Hudgens JW, et al
J Biol Chem. 2016 Apr 7.
Peper

Inhibition of CYP2B6 by Medicinal Plant Extracts: Implication for Use of Efavirenz and Nevirapine-Based Highly Active Anti-Retroviral Therapy (HAART) in Resource-Limited Settings.
Thomford NE, Awortwe C, Dzobo K, et al 
Molecules. 2016 Feb 16;21(2). pii: E211.
Abstract

Efavirenz a nonnucleoside reverse transcriptase inhibitor of first-generation: Approaches based on its medicinal chemistry.
Bastos MM, Costa CC, Bezerra TC, et al
Eur J Med Chem
. 2016 Jan 27;
Abstract

A combined TD-DFT and spectroscopic investigation of the solute-solvent interactions of efavirenz.
Jordaan MA, Singh P, Martincigh BS.  
Spectrochim Acta A Mol Biomol Spectrosc
. 2015 Dec 8;157:204-210.
Abstract

Efavirenz Induced Suicidal Death of Human Erythrocytes.
Bissinger R, Bouguerra G, Al Mamun Bhuyan A,
Cell Physiol Biochem
.
2015;37(6):2496-507
Abstract

Efavirenz a nonnucleoside reverse transcriptase inhibitor of first-generation: Approaches based on its medicinal chemistry.
Bastos MM, Costa CC, Bezerra TC, et al
Eur J Med Chem. 2015 Nov 25;108:455-465.
Abstract

In Vivo Profiling and Distribution of Known and Novel Phase I and Phase II Metabolites of Efavirenz in Plasma, Urine and Cerebro-Spinal Fluid.
Aouri M, Barcelo C, Ternon B, et al
Drug Metab Dispos
. 2015 Nov  9
Abstract

FULL-TEXT ARTICLE
A Randomized Comparison of Anthropomorphic Changes With Preferred and Alternative Efavirenz-Based Antiretroviral Regimens in Diverse Multinational Settings.
Erlandson KM, Taejaroenkul S, Smeaton L,  et al
Open Forum Infect Dis. 2015 Jun 24;2(3):ofv095.
Peper

Lipid-based nutrient supplements do not affect efavirenz but lower plasma nevirapine concentrations in Ethiopian adult HIV patients.
Abdissa A, Olsen MF, Yilma D, et al  
HIV Med
. 2015 May 13.
Abstract

Plasma concentrations of efavirenz, darunavir/ritonavir and raltegravir in HIV-HCV-coinfected patients without liver cirrhosis in comparison with HIV-monoinfected patients.
Calza L, Danese I, Colangeli V, et al
Infect Dis (Lond). 2015 Apr 15:1-12.
Abstract

Correlation between microstructure and bioequivalence in Anti-HIV Drug Efavirenz.
Fandaruff C, Segatto Silva MA,  et al
Eur J Pharm Biopharm
. 2015 Feb 3.
Abstract

Molecularly imprinted nanoparticles prepared by miniemulsion polymerization as a sorbent for selective extraction and purification of efavirenz from human serum and urine.
Pourfarzib M, Shekarchi M, Rastegar H,  et al
J Chromatogr B Analyt Technol Biomed Life Sci
. 2015 Jan 1;974:1-8.
Abstract

Protein-free Efavirenz is Equivalent in Cerebrospinal Fluid & Blood Plasma: Applying the Law of Mass Action to Predict Protein-Free Drug Concentration
Avery LB, Sacktor N, McArthur JC, Hendrix CW.
Antimicrob Agents Chemother
. 2013 Jan 7
.
Abstract

Substantial effect of efavirenz monotherapy on bilirubin levels in healthy volunteers.
Metzger IF, Quigg TC, Epstein N, et al
Curr Ther Res Clin Exp. 2014 Sep 27;76:64-9.
Abstract

Efavirenz Induces Neuronal Autophagy and Mitochondrial Alterations.
Purnell PR, Fox HS.
J Pharmacol Exp Ther. 2014 Aug 26.
Abstract

Differential Subcutaneous Adipose Tissue Gene Expression Pattern with Efavirenz or Lopinavir/ritonavir in Antiretroviral-Naďve Patients: A Randomized Clinical Trial.
Egańa-Gorrońo L, Martínez E, Domingo P, et al
Antimicrob Agents Chemother
. 2014 Aug 25
Abstract

FULL-TEXT ARTICLE
Moving Away from Ritonavir, Abacavir, Tenofovir, and Efavirenz (RATE) - Agents That Concern Prescribers and Patients:
A Feasibility Study and Call for a Trial.
Achhra AC, Boyd MA, Law MG, et al

PLoS One
. 2014 Jun 26;9(6):e99530.
Paper

FULL-TEXT ARTICLE

Efavirenz Promotes β-Secretase Expression and Increased Aβ1-40,42 via Oxidative Stress and Reduced Microglial Phagocytosis: Implications for HIV Associated Neurocognitive Disorders (HAND).
Brown LA, Jin J, Ferrell D, et al
PLoS One. 2014 Apr 23;9(4):e95500.
Paper

Has the time come to abandon efavirenz for first-line antiretroviral therapy?
Raffi F, Pozniak AL, Wainberg MA.
J Antimicrob Chemother
. 2014 Mar 5.
Abstract

The phenolic metabolites of the anti-HIV drug efavirenz: Evidence for distinct reactivities upon oxidation with Frémy's salt.
Harjivan SG, Wanke R, Ferreira da Silva JL, et al
Eur J Med Chem. 2013 Dec 31;74C:7-11
Abstract

Enhanced oral bioavailability of the antiretroviral efavirenz encapsulated in poly(epsilon-caprolactone) nanoparticles by a spray-drying method.
Tshweu L, Katata L, Kalombo L, Chiappetta DA,  et al
Nanomedicine (Lond)
. 2013 Dec 23
Abstract

Low level of efavirenz in HIV-1-infected Thai adults is associated with the CYP2B6 polymorphism.
Sukasem C, Manosuthi W, Koomdee N, et al
Infection. 2013 Nov 30.
Abstract

Factors associated with remaining on initial randomized efavirenz-containing regimens.
Smurzynski M, Wu K, Schouten JT,  et al
AIDS
. 2013 Jul 31;27(12):1887-97.
Abstract

Protein-free efavirenz concentrations in cerebrospinal fluid and blood plasma are equivalent: applying the law of mass action to predict protein-free drug concentration.
Avery LB, Sacktor N, McArthur JC, Hendrix CW.
Antimicrob Agents Chemother
. 2013 Aug;57(8):4095
Abstract

Basis for the Early and Preferential Selection of the E138K Substitution in HIV-1 Reverse Transcriptase with Etravirine.
McCallum M, Oliveira M, Ibanescu RI,  et al
Antimicrob Agents Chemother
. 2013 Jul 15
Abstract

Efavirenz Stimulates HIV-1 Reverse Transcriptase RNase H Activity by a Mechanism Involving Increased Substrate Binding and Secondary Cleavage Activity.
Muchiri JM, Li D, Dykes C, Bambara RA.
Biochemistry
. 2013 Jun 27
Abstract

The HIV antiretroviral drug efavirenz has LSD-like properties.
Gatch MB, González Maeso J, Huang RQ,   et al
Neuropsychopharmacology. 2013 May 24.
Abstract

Cytotoxic effect of Efavirenz is selective against cancer cells and associated with the cannabinoid system.
Hecht M, Harrer T, Büttner M,  et al
AIDS
. 2013 Apr 22.
Abstract

FULL-TEXT ARTICLE
Kinetics of Microbial Translocation Markers in Patients on Efavirenz or Lopinavir/r Based Antiretroviral Therapy.
Vesterbacka J, Nowak P, Barqasho B, . et al
PLoS One
. 2013;8(1):e55038.
Paper

Efavirenz enhances HIV-1 Gag processing at the plasma membrane through Gag-Pol dimerization.
Sudo S, Haraguchi H, Hirai Y,  et al
J Virol
. 2013 Jan 9.
Abstract

ABCB1 4036A>G and 1236C>T Polymorphisms Affect Plasma Efavirenz Levels in South African HIV/AIDS Patients.
Swart M, Ren Y, Smith P, Dandara C.
Front Genet. 2012;3:236
Abstract

FULL-TEXT ARTICLE
HIV-1 RNA May Decline More Slowly in Semen than in Blood following Initiation of Efavirenz-Based Antiretroviral Therapy.
Graham SM, Holte SE, Dragavon JA, et al
PLoS One
. 2012;7(8):e43086.
Paper

Effect of Efavirenz on UDP-Glucuronosyltransferase 1A1, 1A4, 1A6, and 1A9 Activities in Human Liver Microsomes.
Ji HY, Lee H, Lim SR, et al
Molecules. 2012 Jan 17;17:851-60.

Abstract

Study on the structure and vibrational spectra of efavirenz conformers using DFT: Comparison to experimental data.
Mishra S, Tandon P, Ayala AP.
Spectrochim Acta A Mol Biomol Spectrosc
. 2011 Dec 13.
Abstract

Non-linear mixed effects modeling of antiretroviral drug response after administration of lopinavir, atazanavir and efavirenz containing regimens to treatment-naďve HIV-1 infected patients.
Röshammar D, Simonsson US, Ekvall H, et al  
J Pharmacokinet Pharmacodyn
. 2011 Oct 2.
Abstract

Efavirenz and 8-hydroxyefavirenz induce cell death via a JNK- and BimEL-dependent mechanism in primary human hepatocytes.
Bumpus NN.
Toxicol Appl Pharmacol
.
2011 Sep 19
Abstract

Long-term effect of efavirenz autoinduction on plasma/peripheral blood mononuclear cell drug exposure and CD4 count is influenced by UGT2B7 and CYP2B6 genotypes among HIV patients.
Habtewold A, Amogne W, Makonnen E,  et al
J Antimicrob Chemother
. 2011 Aug 16.
Abstract

Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI)-resistant Virus is Stimulated by Efavirenz (EFV) During Early Stages of Infection.
Wang J, Zhang G, Bambara RA, Li D,
J V
irol. 2011 Aug 10.
Abstract

HIV/AIDS Patients Display Lower Relative Bioavailability of Efavirenz than Healthy Subjects.
Mukonzo JK, Nanzigu S, Rekić D,  et al 
Clin Pharmacokinet
. 2011 Aug 1;50(8):
Abstract

The Male Genital Tract Is Not a Pharmacological Sanctuary From Efavirenz.
Avery LB, Bakshi RP, Cao YJ, Hendrix CW.
Clin Pharmacol Ther. 2011 Jun 1.
Abstract

Compromising mitochondrial function with the antiretroviral drug efavirenz induces cell survival-promoting autophagy.
Apostolova N, Gomez-Sucerquia LJ, Gortat A, et al
Hepatology
. 2011 May 29.
Abstract

Effects of nevirapine and efavirenz on human adipocyte differentiation, gene expression, and release of adipokines and cytokines.
Díaz-Delfín J, Del Mar Gutiérrez M, Gallego-Escuredo JM,  et al
Antiviral Res
. 2011 May 17.

Abstract

Study of meta-trajectories of CD4 cells count from taxonomy in the antiretroviral response of efavirenz-based regimen with naive symptomatic patients in Abidjan
Abrogoua DP, Aulagner G, Kablan BJ, Petit C.
Ann Pharm Fr. 2011 Jan;69(1):7-21.
Abstract

Efavirenz concentrations in CSF exceed IC50 for wild-type HIV.
Best BM, Koopmans PP, Letendre SL,  et al
J Antimicrob Chemother
. 2010 Nov 23.
Abstract

Efavirenz Binding Site in HIV-1 Reverse Transcriptase Monomers.
Braz VA, Barkley MD, Jockusch RA, Wintrode PL.
Biochemistry
. 2010 Nov 19.
Abstract

A randomized crossover study to compare efavirenz and etravirine treatment.
Nguyen A, Calmy A, Delhumeau C,  et al
AIDS
. 2010 Nov 11.
Abstract

Differential Effects of Efavirenz and Lopinavir/Ritonavir on Human Adipocyte Differentiation,Gene Expression and Release of Adipokines and Pro-Inflammatory Cytokines.
Gallego-Escuredo1 JM, Del Mar Gutierrez M, Diaz-Delfin J,  et al 
Curr HIV Res
. 2010 Oct 1;
Abstract

Long-Term Efavirenz Autoinduction and Its Effect on Plasma Exposure in HIV Patients.
Ngaimisi E, Mugusi S, Minzi OM
Clin Pharmacol Ther
. 2010 Sep 29.
Abstract

Efavirenz Plasma Concentrations and Cytochrome 2B6 Polymorphisms
Lindfelt T, O'Brien JA, Song JC, et al
Ann Pharmacother
. 2010 Sep 14
Abstract

Impact of Ritonavir, Atazanavir and their Combination on the CYP3A4 Induction Potential of Efavirenz in Primary Human Hepatocytes.
Mugundu GM, Hariparsad N, Desai PB. 
Drug Metab Lett
. 2010 Mar 4.
Abstract

Efavirenz Binding to HIV-1 Reverse Transcriptase Monomers and Dimers.
Braz VA, Holladay LA, Barkley MD.
Biochemistry
. 2009 Dec 29
Abstract

Efavirenz-loaded polymeric micelles for pediatric anti-HIV pharmacotherapy with significantly higher oral bioavailaibility.
Chiappetta DA, Hocht C, Taira C, Sosnik A.
Nanomed
. 2010 Jan;5(1):11-23

Abstract

Efavirenz plasma concentrations did not predict cessation of therapy due to neuropsychiatric symptoms in a large randomized trial.
Read TR, Carey D, Mallon P, et al
AIDS
. 2009 Sep 21.
Abstract

Efavirenz: a decade of clinical experience in the treatment of HIV.
Maggiolo F.
J Antimicrob Chemother
. 2009 Sep 18
Abstract

Non-nucleoside reverse transcriptase inhibitor efavirenz increases monolayer permeability of human coronary artery endothelial cells.
Jamaluddin MS, Lin PH, Yao Q, Chen C.
Atherosclerosis
. 2009 Jul 23
Abstract

In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function.
Iulio JD, Fayet A, Arab-Alameddine M, et al
Pharmacogenet Genomics
. 2009 Feb 20

Abstract
 

Influence of liver fibrosis stage on plasma levels of efavirenz in HIV-infected patients with chronic hepatitis B or C.
Meynard JL, Lacombe K, Poirier JM, et al 
J Antimicrob Chemother
. 2009 Jan 23.
Abstract
 
Physicochemical Characterization of Efavirenz-Cyclodextrin Inclusion Complexes.
Sathigari S, Chadha G, Lee YH,  
AAPS PharmSciTech
. 2009 Jan 16
Abstract
 
Voltammetric studies on the HIV-1 inhibitory drug Efavirenz: The interaction between dsDNA and drug using electrochemical DNA biosensor and adsorptive stripping voltammetric determination on disposable pencil graphite electrode.
Dogan-Topal B, Uslu B, Ozkan SA.
Biosens Bioelectron
. 2008 Dec 9.
Abstract
 
Efavirenz Mannich bases: Synthesis, anti-HIV and antitubercular activities.
Sriram D, Banerjee D, Yogeeswari P. 
J Enzyme Inhib Med Chem. 2008 Nov 13:1.
Abstract
 
Effects of the HIV treatment drugs nevirapine and efavirenz on brain creatine kinase activity.
Streck EL, Scaini G, Rezin GT, et al
Metab Brain Dis.
2008 Sep 24.
Abstract
 
Factors influencing efavirenz and nevirapine plasma concentration: effect of ethnicity, weight and co-medication.
Stöhr W, Back D, Dunn D, et al
Antivir Ther.
2008;13(5):675-85.
Abstract
 
Clinical impact of patient population differences and genomic variation in efavirenz therapy.
King J, Aberg JA.
AIDS.
2008 Aug 20.
Abstract
 
A Study of the Binding Energies of Efavirenz to Wild-Type and K103N/Y181C HIV-1 Reverse
Transcriptase Based on the ONIOM Method.
Srivab P, Hannongbua S. 
ChemMedChem
. 2008 Mar 12
Abstract  
 
Energetic effects for observed and unobserved HIV-1 reverse transcriptase mutations of residues L100, V106, and Y181 in the presence of nevirapine and efavirenz.
Kroeger Smith MB, Rader LH, et al   
Bioorg Med Chem Lett.
2007 Dec 23
Abstract
 
Intracellular Efavirenz Levels in Peripheral Blood Mononuclear Cells from HIV-Infected Individuals.
Tanaka R, Hanabusa H, Kinai E, et al 
Antimicrob Agents Chemother
. 2007 Dec 10
Abstract
 
Efavirenz Accelerates HIV-1 Reverse Transcriptase Ribonuclease H Cleavage Leading to Diminished Zidovudine Excision.
Radzio J, Sluis-Cremer N
Mol Pharmacol. 2007 Nov 16;
Abstract
 
Bioequivalence of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate Single-Tablet Regimen.
Mathias AA, Hinkle J, Menning M, et al 
J Acquir Immune Defic Syndr.
2007 Jul 19;
Abstract
 
Efavirenz: a review.
Vrouenraets SM, Wit FW, van Tongeren J, Lange JM.
Expert Opin Pharmacother.
2007 Apr;8(6):851-71.
Abstract
 
Multilocus genetic interactions and response to efavirenz-containing regimens: an Adult AIDS Clinical Trials Group study.
Motsinger AA, Ritchie MD, Shafer RW, et al  
Pharmacogenet Genomics
. 2006 Nov;16(11):837-845.
Abstract
 
The use of the non-nucleoside reverse transcriptase inhibitors nevirapine and efavirenz in the treatment of patients with a chronic HIV-I infection
van Leth F, Lange JM. 
Ne
d Tijdschr Geneeskd. 2006 Aug 5;150(31):1719-22
Abstract
 
Metabolism of efavirenz and 8-hydroxyefavirenz by P450 2B6 leads to inactivation by two distinct mechanisms.
Bumpus NN, Kent UM, Hollenberg PF
J Pharmacol Exp Ther. 2006 Apr 12;
Abstract
 
Effects of Efavirenz Binding on the Subunit Equilibria of HIV-1 Reverse Transcriptase.
Venezia CF, Howard KJ, Ignatov ME, et al 
Biochemistry. 2006 Mar 7;45(9):2779-89.
Abstract

Pharmacogenetics
       

 
Population Pharmacokinetics Modeling of Unbound Efavirenz, Atazanavir, and Ritonavir in HIV-Infected Subjects With Aging Biomarker
Dumond JB, Chen J, Cottrell M, et al
CPT Pharmacometrics Syst Pharmacol. 2016 Dec 29.
Abstract

Impact of efavirenz pharmacokinetics and pharmacogenomics on neuropsychological performance in older HIV-infected patients.
Sandkovsky U, Podany AT, Fletcher CV, et al
J Antimicrob Chemother. 2016 Sep 21
Abstract

Comprehensive Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Evaluation of Once-Daily Efavirenz 400 and 600 mg in Treatment-Naďve HIV-Infected Patients at 96 Weeks: Results of the ENCORE1 Study.
Dickinson L, Amin J, Else L,  et al 
Clin Pharmacokinet
. 2015 Dec 29.
Abstract

FULL-TEXT ARTICLE
An Expanded Analysis of Pharmacogenetics Determinants of Efavirenz Response that Includes 3'-UTR Single Nucleotide Polymorphisms among Black South African HIV/AIDS Patients.
Swart M, Evans J, Skelton M, et al
Front Genet
. 2016 Jan 7;6:356.
Paper

Pharmacogenetics of pregnancy-induced changes in efavirenz pharmacokinetics.
Olagunju A, Bolaji O, Amara A,  et al
Clin Pharmacol Ther
. 2015 Mar;97(3):298-306

Abstract

Simultaneous plasma and genital pharmacokinetics and pharmacodynamics of atazanavir and efavirenz in HIV-infected women starting therapy.
Neely M, Louie S, Xu J,  et a

J Clin Pharmacol
. 2015 Feb 12
Abstract

Pharmacogenetics of plasma efavirenz exposure in HIV-infected adults and children in South Africa.
Sinxadi PZ, Leger PD, McIlleron H,  et al
Br J Clin Pharmacol. 2015 Jan 22.
Abstract

CYP2B6 genotype, but not rifampicin-based anti-TB cotreatments, explains variability in long-term efavirenz plasma exposure.
Mukonzo JK, Nanzigu S, Waako P, et al
Pharmacogenomics. 2014 Aug;15(11):1423-1435.
Abstract

FULL-TEXT ARTICLE
Pharmacogenetic-Based Efavirenz Dose Modification: Suggestions for an African Population and the Different CYP2B6 Genotypes.
Mukonzo JK, Owen JS, Ogwal-Okeng J, et al  
PLoS One
. 2014 Jan 31;9(1):e86919

Paper

Pharmacogenetics and clinical biomarkers for subtherapeutic plasma efavirenz concentration in HIV-1 infected Thai adults.
Sukasem C, Chamnanphon M, Koomdee N,  et al
Drug Metab Pharmacokinet. 2014 Jan 28.
Abstract

Pharmacometric Characterization of Efavirenz Developmental Pharmacokinetics and Pharmacogenetics in Human Immunodeficiency Virus Infected Children.
Salem AH, Fletcher CV, Brundage RC.
Antimicrob Agents Chemother. 2013 Oct 21
Abstract

Population pharmacogenetic-based pharmacokinetic modeling of efavirenz, 7-hydroxy- and 8-hydroxyefavirenz.
Abdelhady AM, Desta Z, Jiang F, et al
J Clin Pharmacol
. 2013 Oct 19
Abstract

Impact of pharmacogenetics on CNS side effects related to efavirenz.
Sánchez Martín A, Cabrera Figueroa S, Cruz Guerrero R, et al
Pharmacogenomics
. 2013 Jul;14(10):1167-78
Abstract

CYP2B6 Pharmacogenetics-Based in vitro-in vivo Extrapolation (IVIVE) of Efavirenz Clearance by PBPK Modeling.
Xu C, Quinney SK, Guo Y, et al
Drug Metab Dispos
. 2013 Jul 11
Abstract

FULL-TEXT PDF ARTICLE
Influence of efavirenz pharmacokinetics and pharmacogenetics on neuropsychological disorders in Ugandan HIV-positive patients with or without tuberculosis: a prospective cohort study.
Mukonzo JK, Okwera A, Nakasujja N,  et al
BMC Infect Dis
. 2013 Jun 4;13(1):261
Paper

Neuropsychometric Correlates of Efavirenz Pharmacokinetics and Pharmacogenetics Following a Single Oral Dose.
Johnson DH, Gebretsadik T, Shintani A,  et alr
J Clin Pharmacol
. 2012 Sep 7
Abstract

In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function.
Iulio JD, Fayet A, Arab-Alameddine M, et al
Pharmacogenet Genomics
. 2009 Feb 20
Abstract

Pharmacogenetics-Based Population Pharmacokinetic Analysis of Efavirenz in HIV-1-Infected Individuals.
Arab-Alameddine M, Di Iulio J, Buclin T, et al 
Clin Pharmacol Ther
. 2009 Feb 18
Abstract
 

  Pharmacogenetics of Long-Term Responses to Antiretroviral Regimens Containing Efavirenz and/or Nelfinavir: An Adult AIDS Clinical Trials Group Study.
Haas DW, Smeaton LM, Shafer RW,
Infect Dis.
2005 Dec 1;192(11):1931-42.

Abstract

Pharmacokinetics
       

 
Impact of efavirenz pharmacokinetics and pharmacogenomics on neuropsychological performance in older HIV-infected patients.
Sandkovsky U, Podany AT, Fletcher CV, et al
J Antimicrob Chemother
. 2016 Sep 21
Abstract

Comparison of population pharmacokinetics based on steady-state assumption versus electronically monitored adherence to lopinavir, atazanavir, efavirenz, and etravirine: A retrospective study.
Aline F, Aurélie R, Matthias C, et al
Ther Drug Monit. 2016 Mar 1.
Abstract

Efavirenz (EFV) but not Atazanavir/ritonavir (ATV/r) Significantly Reduces Atovaquone Concentrations in HIV-infected Subjects.
Calderón MM, Penzak SR, Pau AK,,et al
Clin Infect Dis
. 2016 Jan 20.
Abstract

Comparison of the in vivo pharmacokinetics and in vitro dissolution of branded versus generic efavirenz formulation in HIV-infected patients.
Gervasoni C, ChemD SB, Cerea M, et al
Ther Drug Monit
. 2015 Dec 30.
Abstract

FULL=TEXT ARTICLE
Importance of Ethnicity, CYP2B6 and ABCB1 Genotype for Efavirenz Pharmacokinetics and Treatment Outcomes: A Parallel-Group Prospective Cohort Study in Two Sub-Saharan Africa Populations.
Ngaimisi E, Habtewold A, Minzi O,  et al
PLoS One
. 2013 Jul 5;8(7):e67946.
Paper

FULL-TEXT PDF ARTICLE
Influence of efavirenz pharmacokinetics and pharmacogenetics on neuropsychological disorders in Ugandan HIV-positive patients with or without tuberculosis: a prospective cohort study.
Mukonzo JK, Okwera A, Nakasujja N,  et al
BMC Infect Dis
. 2013 Jun 4;13(1):261
Paper

Pharmacokinetic Modelling of Efavirenz, Atazanavir, Lamivudine and Tenofovir in the Female Genital Tract of HIV-Infected Pre-Menopausal Women.
Dumond JB, Nicol MR, Kendrick RN, et al
Clin Pharmacokinet. 2012 Oct 9
Abstract

FULL-TEXT ARTICLE
Pharmacokinetics and Pharmacodynamics of Darunavir and Etravirine in HIV-1-Infected, Treatment-Experienced Patients in the Gender, Race, and Clinical Experience (GRACE) Trial.

Carten ML, Kiser JJ, Kwara A, et al  
Infect Dis Obstet Gynecol
. 2012;2012:137192|
Paper

Associations Between ABCB1, CYP2A6, CYP2B6, CYP2D6, and CYP3A5 Alleles in Relation to Efavirenz and Nevirapine Pharmacokinetics in HIV-Infected Individuals.
Heil SG, van der Ende ME, Schenk PW, et al
Ther Drug Monit
. 2012 Feb 17.
Abstract

Pharmacokinetics of the nonnucleoside reverse transcriptase inhibitor efavirenz among HIV-infected Ugandans.
Nanzigu S, Eriksen J, Makumbi F, et al
HIV Med
. 2011 Nov 22.
Abstract

Oral pharmacokinetics of the anti-HIV efavirenz encapsulated within polymeric micelles.
Chiappetta DA, Hocht C, Taira C, Sosnik A.
Biomaterials
. 2010 Dec 24
Abstract

Influence of host genetic factors on efavirenz plasma and intracellular pharmacokinetics in HIV-1-infected patients.
Elens L, Vandercam B, Yombi JC, et al
Pharmacogenomics
. 2010 Sep;11(9):1223-34.
Abstract

Pharmacokinetics of Darunavir 900mg and Ritonavir 100mg Once Daily when Co-administered with Efavirenz 600mg Once Daily in Healthy Volunteers.
Soon GH, Shen P, Yong EL, et al
Antimicrob Agents Chemother
2010 Apr 12
Abstract

Pharmacokinetics of Plasma Efavirenz and CYP2B6 Polymorphism in Southern Chinese.
To KW, Liu ST, Cheung SW, et al
Ther Drug Monit
. 2009 Jun 11
Abstract

Population Pharmacokinetics of Efavirenz in HIV Patients: Influence of the CYP2B6 Genotype.
Cabrera SE, Santos D, Valverde MP, et al 
Antimicrob Agents Chemother. 2009 May 11
Abstract

The pharmacokinetics and pharmacogenomics of efavirenz and lopinavir/ritonavir in HIV-infected persons requiring hemodialysis.
Gupta SK, Rosenkranz SL, Cramer YS, et al   
AIDS.
2008 Oct 1;22(15):1919-1927
Abstract
 

High prevalence of the CYP2B6 516G-->T(*6) variant and effect on the population pharmacokinetics of efavirenz in HIV/AIDS outpatients in Zimbabwe.
Nyakutira C, Röshammar D, Chigutsa E, et al 
Eur J Clin Pharmacol.
2007 Dec 5
Abstract
 
Multiple-Dose Pharmacokinetics of Efavirenz with and without the Use of Rifampicin in HIV-Positive Patients.
Matteelli A, Regazzi M, Villani P, et al
Curr HIV Res
. 2007 May;5(3):349-53.
Abstract
 
Predictive Value of Known and Novel Alleles of CYP2B6 for Efavirenz Plasma Concentrations in HIV-infected Individuals.
Rotger M, Tegude H, Colombo S, et al 
Clin Pharmacol T
her. 2007 Jan 18;
Abstract
 
Efavirenz in Plasma from HIV-Infected Patients Does Not Directly Block Reverse Transcriptase Activity in Cell-Free Assays But Inhibits HIV Replication in Cellular Assays.
Burrer R, Spiridon G, Einius-Haessig S, et al 
AIDS Res Hum Retroviruses. 2006 Sep;22(9):865-9.
Abstract
 
Ritonavir, Saquinavir and Efavirenz, but not Nevirapine, Inhibit Bile Acid Transport in Human and Rat Hepatocytes.
McRae MP, Lowe CM, Tian X  ,et al
J Pharmacol Exp
Ther. 2006 May 23;
Abstract
 
Interpatient variability in the pharmacokinetics of the HIV non-nucleoside reverse transcriptase inhibitor efavirenz: the effect of gender, race, and CYP2B6 polymorphism.
Burger D, van der Heiden I, la Porte C, et al
Br J Clin Pharmacol.
2006 Feb;61(2):148-54

Abstract

ntracellular and plasma pharmacokinetics of efavirenz in HIV-infected individuals.
Almond LM, Hoggard PG, Edirisinghe D, et al  
J Antimicrob Chemother. 2005 Sep 1;
Abstract
 

Pharmacokinetics of nelfinavir and efavirenz in antiretroviral-naive, human immunodeficiency virus-infected subjects when administered alone or in combination with nucleoside analog
reverse transcriptase inhibitors.
Smith PF, Robbins GK, Shafer RW, et al
Antimicrob Agents Chemother.
2005 Aug;49(8):3558-61.
Abstract
 
Amprenavir and Efavirenz Pharmacokinetics before and after the Addition of Nelfinavir, Indinavir, Ritonavir, or Saquinavir in Seronegative Individuals.
Morse GD, Rosenkranz S, Para MF 
Antimicrob Agents Chemother.
2005 Aug;49(8):3373-8
Abstract
.
Population Pharmacokinetics of Efavirenz in an Unselected Cohort of HIV-1-Infected Individuals.
Kappelhoff BS, Huitema AD, Yalvac Z,   
Clin Pharmacokinet.
2005;44(8):849-61.
Abstract
 
Quantum study of mutational effect in binding of efavirenz to HIV-1 RT.
Mei Y, He X, Xiang Y, Zhang DW, Zhang JZ.
Proteins. 2005 Mar 23;
Abstract
 
Efavirenz enhances the proteolytic processing of an HIV-1 pol polyprotein precursor and reverse transcriptase homodimer formation.
Tachedjian G, Moore KL, Goff SP, Sluis-Cremer N  .
FEBS Lett.
2005 Jan 17;579(2):379-384
Abstract
 
Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study.
Haas DW, Ribaudo HJ, Kim RB, et al
AIDS.
2004 Dec 3;18(18):2391-2400.
Abstract
 
Homozygous CYP2B6 *6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimens.
Tsuchiya K, Gatanaga H, Tachikawa N, et al 
Biochem Biophys Res Commun.
2004 Jul 9;319(4):1322-6.
Abstract

The cytochrome P450 2B6 is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as substrate marker
of CYP2B6 catalytic activity.

Ward BA, Gorski CJ, Jones DR, et al.
J Pharmacol Exp Ther 2003 Apr 3;I
Abstract

Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection.
Csajka C, Marzolini C, Fattinger K,
 et al.
Clin Pharmacol Ther 2003 Jan;73(1):20-30
Abstract

Population Pharmacokinetics and Pharmacodynamics of Efavirenz, Nelfinavir, and Indinavir: Adult AIDS Clinical Trial Group Study 398.
Pfister M, Labbe L, Hammer SM, et al.
Antimicrob Agents Chemother
2003 Jan;47(1):130-137

Abstract

 

Drug/Drug Interactions
 

 
Physiologically Based Pharmacokinetic Modeling to Predict Drug-Drug Interactions with Efavirenz Involving Simultaneous Inducing and Inhibitory Effects on Cytochromes.
Marzolini C, Rajoli R, Battegay M,  et al
Clin Pharmacokinet
. 2016 Sep 7.
Abstract

Evaluation of Drug-Drug Interactions between Direct-Acting Anti-Hepatitis C Virus Combination Regimens and the HIV-1 Antiretroviral Agents Raltegravir, Tenofovir, Emtricitabine, Efavirenz, and Rilpivirine.
Khatri A, Dutta S, Dunbar M, et al
Antimicrob Agents Chemother
. 2016 Apr 22;60(5):2965-71.
Abstract

Inhibition of efavirenz metabolism by sertraline and nortriptyline and their effect on the efavirenz plasma concentrations.
Melis V, Usach I, Gandía P, Peris JE.
Antimicrob Agents Chemother
. 2015 Dec 7.
Abstract

Preclinical assessment of the interactions between the antiretroviral drugs, ritonavir and efavirenz, and the tyrosine kinase inhibitor erlotinib.
Deeken JF, Beumer JH, Anders NM, et al
Cancer Chemother Pharmacol. 2015 Sep 2
Abstract

FULL-TEXT ARTICLE
Effects of enzyme inducers efavirenz and tipranavir/ritonavir on the pharmacokinetics of the HIV integrase inhibitor dolutegravir.
Song I, Borland J, Chen S,et al
Eur J Clin Pharmacol
. 2014 Oct;70(10):1173-9.
Paper

Effects of enzyme inducers efavirenz and tipranavir/ritonavir on the pharmacokinetics of the HIV integrase inhibitor dolutegravir.
Song I, Borland J, Chen S, Guta P, et al
Eur J Clin Pharmacol
.
2014 Aug 23.
Abstract

Potential Interactions between HIV Drugs, Ritonavir and Efavirenz and Anticancer Drug, Nilotinib - A Study in Primary Cultures of Human Hepatocytes That is Applicable to HIV Patients with Cancer.
Pillai VC, Parise RA, Christner SM,  et al
J Clin Pharmacol
. 2014 May 20.
Abstract

Effect of antiretroviral therapy including lopinavir/ritonavir or efavirenz on etonogestrel-releasing implant pharmacokinetics in HIV-positive women.
Vieira CS, Bahamondes MV, de Souza RM,  et al

J Acquir Immune Defic Syndr
. 2014 May 4.
Abstract

The role of competitive binding to human serum albumin on efavirenz-warfarin interaction: a nuclear magnetic resonance study.
Wanke R, Harjivan SG, Pereira SA, et al
Int J Antimicrob Agents
. 2013 Sep 1
Abstract

Ritonavir and Efavirenz Significantly Alter the Metabolism of Erlotinib - An Observation in Primary Cultures of Human Hepatocytes That is Relevant to HIV Patients with Cancer.
Pillai VC, Venkataramanan R, Parise RA,  et al
Drug Metab Dispos. 2013 Aug 2
Abstract

Interactions Between Alcohol and the Antiretroviral Medications Ritonavir or Efavirenz.
McCance-Katz EF, Gruber VA,  et al
J Addict Med
. 2013 May 9.
Abstract

Prediction of drug-drug Interactions Between Various Antidepressants and Efavirenz or Boosted Protease Inhibitors Using a Physiologically Based Pharmacokinetic Modelling Approach.
Siccardi M, Marzolini C, Seden K et al
Clin Pharmacokinet. 2013 Mar 12
Abstract

Unexpected Drug-Drug Interactions in Human Immunodeficiency Virus (HIV) Therapy: Induction of UGT1A1 and Bile Efflux Transporters by Efavirenz.
Lee LS, Pham P, Flexner C.
Ann Acad Med Singapore
. 2012 Dec;41(12):559-62.
Abstract

Potential benefits of cyproheptadine in HIV-positive patients under treatment with antiretroviral drugs including efavirenz.
Dabaghzadeh F, Khalili H, Ghaeli P, Dashti-Khavidaki S.
Expert Opin Pharmacother. 2012 Nov 10
Abstract

Significant pharmacokinetic interactions between artemether/lumefantrine and efavirenz or nevirapine in
HIV-infected Ugandan adults.
Byakika-Kibwika P, Lamorde M, Mayito J,   et al
J Antimicrob Chemother. 2012 Jun 11.
Abstract

Pharmacokinetic Interactions between the Hormonal Emergency Contraception, Levonorgestrel (Plan B), and Efavirenz.
Carten ML, Kiser JJ, Kwara A, et al  
Infect Dis Obstet Gynecol
. 2012;2012:137192
Abstract

Modest but Variable Effect of Rifampin on Steady-State Plasma Pharmacokinetics of Efavirenz in Healthy African-American and Caucasian Volunteers.
Kwara A, Tashima KT, Dumond JB, et al
A
ntimicrob Agents Chemother
. 2011 Apr
Abstract

The effect of efavirenz on the pharmacokinetics of an oral contraceptive containing ethinyl estradiol and norgestimate in healthy HIV-negative women.
Sevinsky H, Eley T, Persson A, et al
Antivir Ther. 2011;16(2):149-56.
Abstract

Decreased plasma efavirenz concentrations in a patient receiving rifabutin.
Hsu O, Hill CJ, Kim M, Tan B, O'Brien JG.
Am J Health Syst Pharm. 2010 Oct 1;67(19):1611-4.
Abstract

Pharmacokinetics of Darunavir 900mg and Ritonavir 100mg Once Daily when Co-administered with Efavirenz 600mg Once Daily in Healthy Volunteers.
Soon GH, Shen P, Yong EL, et al
Antimicrob Agents Chemother
2010 Apr 12
Abstract

Pharmacokinetic interaction between efavirenz and dual protease inhibitors in healthy volunteers.
Ma Q, Forrest A, Rosenkranz SL, et al  
Biopharm Drug Dispos.
2007 Nov 27;29(2):91-101
Abstract
 

Outcomes of dosage adjustments used to manage antiretroviral drug interactions.
Park-Wyllie LY, Levine MA, Holbrook A, et al
Clin Infect Dis.
2007 Oct 1;45(7):933-6.
Abstract
 
Drug-drug interaction between itraconazole and efavirenz in a patient with AIDS and disseminated histoplasmosis.
Koo HL, Hamill RJ, Andrade RA.
Clin Infect Dis. 2007 Sep 15;45(6):e77-9
Abstract
 
Pharmacokinetic interaction between TMC114/r and efavirenz in healthy volunteers.
Sekar VJ, De Pauw M, Mariën K,   et al
Antivir Ther
. 2007;12(4):509-14
Abstract
 

Effect of efavirenz on the pharmacokinetics of ketoconazole in HIV-infected patients.
Sriwiriyajan S, Mahatthanatrakul W, Ridtitid W, Jaruratanasirikul S.
Eur J Clin Pharmacol. 2007 Mar 8
Abstract
 
Assessment of Drug-Drug Interactions Between Tenofovir Disoproxil Fumarate and the Nonnucleoside Reverse Transcriptase Inhibitors Nevirapine and Efavirenz in HIV-Infected Patients.
Droste JA, Kearney BP, Hekster YA, Burger DM.
J Acquir Immune Defic Syndr. 2006 Jan 1;41(1):37-43.
Abstract
 
Evaluation of the Drug Interaction Between Rifabutin and Efavirenz in Patients with HIV Infection and Tuberculosis.
Weiner M, Benator D, Peloquin CA, et al 
Clin Infect Dis. 2005 Nov 1;41(9):1343-9.
Abstract
 
Effect of Efavirenz on the Pharmacokinetics of Simvastatin, Atorvastatin, and Pravastatin: Results of AIDS Clinical Trials Group 5108 Study.
Gerber JG, Rosenkranz SL, Fichtenbaum CJ, et al 
J Acquir Immune Defic Syndr. 2005 Jul 1;39(3):307-312.
Abstract
 
Effects of Valproic Acid Coadministration on Plasma Efavirenz and Lopinavir Concentrations in Human Immunodeficiency Virus-Infected Adults.
Dicenzo R, Peterson D, Cruttenden K, et al 
Antimicrob Agents Chemother
. 2004 Nov;48(11):4328-433
Abstract
 
Safety and Antiretroviral Effectiveness of Concomitant Use of Rifampicin and Efavirenz for Antiretroviral-Naive Patients in India Who Are Coinfected With Tuberculosis and HIV-1.
Patel A, Patel K, Patel J, et al   
J Acquir Immune Defic Syndr.
2004 Sep 1;37(1):1166-1169.
Abstract

The Pharmacokinetics of Methadone in HIV Positive Patients Receiving the Non-nucleoside Reverse Transcriptase Inhibitor Efavirenz
Susan M Clarke, Fiona M Mulcahy, John Tjia, et al.
Br J Clin Pharm 2001:51:3:213-218
Abstract

FULL-TEXT ARTICLE
Selective interaction of the human immunodeficiency virus type 1 reverse transcriptase nonnucleoside inhibitor efavirenz and its thio-substituted analog with different enzyme-
substrate complexes.
Maga G, Ubiali D, Salvetti R, et al.  
Antimicrob Agents Chemother 2000 May;44(5):1186-1194
Paper

 

Viral Dynamics
          

 
FULL-TEXT ARTICLE
Factors associated with HIV viral load "blips" and the relationship between self-reported adherence and efavirenz blood levels on blip occurrence: a case-control study.
Farmer A, Wang X, Ganesan A, et al
AIDS Res Ther
. 2016 Mar 22;13:16.
Paper

Genome-wide association study of virologic response with efavirenz-containing or abacavir-containing regimens in AIDS clinical trials group protocols.
Lehmann DS, Ribaudo HJ, Daar ES,  et al
Pharmacogenet Genomics. 2014 Nov 28.
Abstract

HIV-1 Amino Acid Changes Among Participants With Virologic Failure: Associations With First-line Efavirenz or Atazanavir Plus Ritonavir and Disease Status.
Mollan K, Daar ES, Sax PE,  et al  
J Infect Dis. 2012 Nov 12.
Abstract

Differential Effects of Efavirenz, Lopinavir/r, and Atazanavir/r on the Initial Viral Decay Rate in Treatment Naďve HIV-1-Infected Patients.
Edén A, Andersson LM, Andersson O, et al
AIDS Res Hum Retroviruses
. 2010 May 10.
Abstract

Racial differences in virologic failure associated with adherence and quality of life on efavirenz-containing regimens for initial HIV therapy: results of ACTG A5095.
Schackman BR, Ribaudo HJ, Krambrink A, et al
J Acquir Immune Defic Syndr.
2007 Dec 15;46(5):547-54.
Abstract

Predictors of Residual Viremia in HIV-Infected Patients Successfully Treated with Efavirenz and Lamivudine plus either Tenofovir or Stavudine.
Havlir DV, Koelsch KK, Strain MC, et al 
J Infect Dis.
2005 Apr 1;191(7):1164-8.
Abstract
 

Predictors of virologic failure and resistance in HIV-infected patients treated with nevirapine- or efavirenz-based antiretroviral therapy.
Parienti JJ, Massari V, Descamps D, et al
Clin Infect Dis. 2004 May 1;38(9):1311-6.
Abstract
 

Inhibitor-Based Highly Active Antiretroviral Therapy in a Cohort of Antiretroviral-Naive Patients With Advanced HIV Infection (EfaVIP 2 Study).
The EfaVIP Cohort Study Group.
J Acquir Immune Defic Syndr.
2004 Apr 20;35(4):343-350.
Abstract
 

Resistance
 

 
Increase of HIV-1 K103N Transmitted Drug Resistance and Its Association with Efavirenz Use in South Korea.
Chin BS, Shin HS, Kim G,  et al
AIDS Res Hum Retroviruses
. 2015 Mar 31.
Abstract

Sensitive testing of plasma HIV-1 RNA and Sanger sequencing of cellular HIV-1 DNA for the detection of drug resistance prior to starting first-line antiretroviral therapy with etravirine or efavirenz.
Geretti AM, Conibear T, Hill A,  et al
J Antimicrob Chemother
. 2013 Nov 27
Abstract

High predictive value of CYP2B6 SNPs for steady-state plasma efavirenz levels in South African HIV/AIDS patients.
Swart M, Skelton M, Ren Y,  et al
Pharmacogenet Genomics
. 2013 Jun 14.
Abstract

FULL-TEXT ARTICLE
Panel of prototypical recombinant infectious molecular clones resistant to nevirapine, efavirenz, etravirine, and rilpivirine.
Balamane M, Varghese V, Melikian GL, et al
Antimicrob Agents Chemother. 2012 Aug;56(8):4522-4
Paper

Presence of 3TC/FTC is associated with a reduced emergence of NNRTI mutations in an efavirenz-based intermittent antiretroviral treatment.
Trancart S, Charreau I, Marchou B, et al
Antimicrob Agents Chemother. 2011 Dec 27
Abstract

TFULL-TEXT ARTICLE
Resistance Patterns Selected by Nevirapine vs. Efavirenz in HIV-Infected Patients Failing First-Line Antiretroviral Treatment: A Bayesian Analysis
Ngo-Giang-Huong N,  Jourdain G, Amzal B, et al
PLoS ONE
6(11): e27427
Paper

FULL-TEXT ARTICLE
Minor HIV-1 Variants with the K103N Resistance Mutation during Intermittent Efavirenz-Containing Antiretroviral Therapy and Virological Failure.

Delobel P, Saliou A, Nicot F, et al
PLoS ON
E
6(7): e21813

Paper

Genotypic Resistance at Viral Rebound among Patients Who Received Lopinavir/ritonavir- or Efavirenz-Based First Antiretroviral Therapy in South Africa.
Dlamini JN, Hu Z, Ledwaba J, Morris L
J Acquir Immune Defic Syndr. 2011 Jun 18.
Abstract

The non-nucleoside reverse transcriptase inhibitor efavirenz stimulates replication of human immunodeficiency virus type 1 harboring certain
non-nucleoside resistance mutations.
Wang J, Liang H, Bacheler L, et al
Virology
. 2010 Apr 15
Abstract

Combination of V106I and V179D Polymorphic Mutations in Human Immunodeficiency Virus Type 1 Reverse Transcriptase Confers Resistance to Efavirenz and Nevirapine but not to Etravirine.
Gatanaga H, Ode H, Hachiya A,  et al 
Antimicrob Agents Chemother
. 2010 Feb 1
Abstract

Low-Frequency K103N Strengthens the Impact of Transmitted Drug Resistance on Virologic Responses to First-Line Efavirenz or Nevirapine-Based Highly Active Antiretroviral Therapy.
Geretti AM, Fox ZV, Booth CL,
J Acquir Immune Defic Syndr
. 2009 Sep 22
Abstract

Variability in the plasma concentration of efavirenz and nevirapine is associated with genotypic resistance after treatment interruption.
Darwich L, Esteve A, Ruiz L, et al
Antivir Ther
. 2008;13(7):945-51.
Abstract
 

Bayesian network analyses of resistance pathways against efavirenz and nevirapine.
Deforche K, Camacho RJ, Grossman Z, et al   
AIDS.
2008 Oct 18;22(16):2107-15.
Abstract
 
Preexisting Resistance to Nonnucleoside Reverse-Transcriptase Inhibitors Predicts VirologicFailure of an Efavirenz-Based Regimen in Treatment-Naive HIV-1-Infected Subjects.
Kuritzkes DR, Lalama CM, Ribaudo HJ, et al
 J Infect Dis. 2008 Feb 12
Abstract
 
Comparison of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDA.
Bannister WP, Ruiz L, Cozzi-Lepri A, et al  
AIDS
. 2008 Jan 30;22(3):367-76
Abstract
 
Relative replication fitness of efavirenz-resistant mutants of HIV-1: Correlation with frequency during clinical therapy and evidence of compensation for the reduced fitness of K103N + L100I
by the nucleoside resistance mutation L74V.
Koval CE, Dykes C, Wang J, Demeter LM.   
Virology.
2006 Jun 20;
Abstract
 
Genotypic and phenotypic resistance patterns at virological failure in a simplification trial with nevirapine, efavirenz or abacavir.
de Echaguen AO, Arnedo M, Xercavins M, et al
AIDS.
2005 Sep 2;19(13):1385-1391.
Abstract
 
The efavirenz-induced increase in HDL-cholesterol is influenced by the multidrug resistance  gene 1 C3435T polymorphism.
Alonso-Villaverde C, Coll B, Gomez F, et al 
AIDS.
2005 Feb 18;19(3):341-2.
Abstract
 
Mutations in HIV-1 Reverse Transcriptase Potentially Associated with Hypersusceptibility to  Nonnucleoside Reverse-Transcriptase Inhibitors: Effect on Response to Efavirenz-Based Therapy in an Urban Observational Cohort.
Tozzi V, Zaccarelli M, Narciso P, et al
J Infect Dis. 2004 May 1;189(9):1688-95

Abstract

Development of drug resistance in HIV-1 patients receiving a combination of stavudine, lamivudine and efavirenz.
Re MC, Monari P, Bon I, et al  
Int J Antimicrob Agents 2002 Sep;20(3):223
Abstract

Resistance profile and cross-resistance of HIV-1 among patients failing a non-nucleoside reverse transcriptase inhibitor-containing regimen.
Delaugerre C, Rohban R, Simon A. et al.
 
J Med Virol 2001  Nov;65(3):445-8
Abstract


FULL-TEXT ARTICLE

Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz
combination therapy.
Bacheler LT, Anton ED, Kudish P, Baker D. et al

Antimicrob Agents Chemother 2000 Sep;44(9):2475-2484

Paper

 

Diagnostics/Drug Monitoring
 

 
A validated liquid chromatography tandem mass spectrometry method for the analysis of efavirenz in 0.2 mg hair samples from HIV-infected patients.
Johnston J, Orrell C, Smith P, et al
Rapid Commun Mass Spectrom
. 2018 Feb 8.  
Abstract

Development and validation of a liquid chromatography-MS/MS method for simultaneous quantification of tenofovir and efavirenz in biological tissues and fluids.
Barreiros L, Cunha-Reis C, Silva EM,  et al
J Pharm Biomed Anal. 2016 Dec 27;136
Abstract

Cost-effectiveness of CYP2B6 genotyping to optimize efavirenz dosing in HIV clinical practice.
Schackman BR, Haas DW, Park SS,et al
Pharmacogenomics
. 2015 Nov 26.
Abstract

An Investigation of Liquid Chromatography-Mass Spectral Attributes and Analytical Performance Characteristics of Tenofovir, Emtricitabine and Efavirenz in Human Plasma.
Ndolo SM, Sichilongo K, Massele A,  et al
J Anal Toxicol
. 2015 Oct 20.
Abstract

A Validated Method for Quantification of Efavirenz in Dried Blood Spots (DBS) using HPLC-MS/MS.
Amara AB, Else LJ, Tjia J,  et al
Ther Drug Monit
. 2014 Aug 26
Abstract

Evaluation of an immunoassay for determination of plasma efavirenz concentrations in resource-limited settings.
Abdissa A, Wiesner L, McIlleron H,  et al
J
Int AIDS Soc. 2014 Jun 5;17(1):18979.
Abstract

Quantification of cell-associated atazanavir, darunavir, lopinavir, ritonavir, and efavirenz concentrations in human mononuclear cell extracts.
Podany AT, Winchester LC, Robbins BL, Fletcher CV.
Antimicrob Agents Chemother. 2014 May;58(5):2866-70
Abstract

FULL-TEXT ARTICLE
Therapeutic Drug Monitoring and Pharmacogenetic Study of HIV-Infected Ethnic Chinese Receiving Efavirenz-Containing Antiretroviral Therapy with or without Rifampicin-Based Anti-Tuberculous Therapy.
Lee KY, Lin SW, Sun HY,  et al
PLoS One
. 2014 Feb 14;9(2):e88497.
Paper

Sensitive testing of plasma HIV-1 RNA and Sanger sequencing of cellular HIV-1 DNA for the detection of drug resistance prior to starting first-line antiretroviral therapy with etravirine or efavirenz.
Geretti AM, Conibear T, Hill A,  et al
J Antimicrob Chemother
. 2013 Nov 27
Abstract

A rapid and selective HPLC-UV method for the quantitation of efavirenz in plasma from patients on concurrent HIV/AIDS and tuberculosis treatments.
Bienvenu E, Hoffmann KJ, Ashton M, Kayumba P
Biomed Chromatogr. 2013 Jun 18
Abstract

FULL-TEXT  ARTICLE
A sensitive and selective liquid chromatography/tandem mass spectrometry method for quantitative analysis of efavirenz in human plasma.
Srivastava P, Moorthy GS, Gross R, Barrett JS.
PLoS One
. 2013 Jun 5;8(6):e63305.
Paper

Determination of Efavirenz in Human Dried Blood Spots by Reversed-phase High-performance Liquid Chromatography With UV Detection.
Hoffman JT, Rossi SS, Espina-Quinto R, et al
Ther Drug Monit. 2013 Apr;35(2):203-8
Abstract

Quantitative analysis of the effect of zidovudine, efavirenz, and ritonavir on insulin aggregation by multivariate curve resolution alternating least squares of infrared spectra.
Martí-Aluja I, Ruisánchez I, Larrechi MS
Anal Chim Acta. 2013 Jan 14;760:16-24
Abstract

Use of dried blood spots for the determination of plasma concentrations of nevirapine and efavirenz.
Kromdijk W, Mulder JW, Rosing H, et al
J Antimicrob Chemother. 2012 Feb 1
Abstract

Functionalized quantum dots with dopamine dithiocarbamate as the matrix for the quantification of efavirenz in human plasma and as affinity probes for rapid identification of microwave tryptic digested proteins in MALDI-TOF-MS.
Kailasa SK, Wu HF.
J Proteomics. 2011 Dec 20
Abstract

Evidence-based Therapeutic Drug Monitoring for Efavirenz
Solas C, Gagnieu MC.
Therapie. 2011 May-Jun;66(3):197-205.
Abstract

Usefulness of Methadone Plasma Concentration Measurement in Patients Receiving
Nevirapine or Efavirenz.
Pelet A, Favrat B, Cavassini M, et al
Am J Drug Alcohol Abuse
. 2011 Jun 23
Abstract

Rapid HCP5 single-nucleotide polymorphism genotyping: A simple allele-specific PCR method for prediction of hypersensitivity reaction to Abacavir.
Galván CA, Elbarcha OC, Fernández EJ, et al
Clin Chim Acta. 2011 Jul 15;412(15-16
Abstract

The relation between treatment outcome and efavirenz, atazanavir or lopinavir exposure in the NORTHIV trial of treatment-naďve HIV-1 infected patients.
Josephson F, Andersson MC, Flamholc L, et al
Eur J Clin Pharmacol
. 2009 Dec 5.
Abstract

A liquid chromatography-tandem mass spectrometry assay for quantification of nevirapine, indinavir, atazanavir, amprenavir, saquinavir, ritonavir, lopinavir, efavirenz, tipranavir, darunavir
and maraviroc in the plasma of patients infected with HIV.
Martin J, Deslandes G, Dailly E, et al 
J Chromatogr B Analyt Technol Biomed Life Sci
. 2009 Aug 3
Abstract

Rapid method for the quantitative determination of efavirenz in human plasma.
Mogatle S, Kanfer I. 
J Pharm Biomed Anal. 2009 Mar 20
Abstract

Determination of abacavir, amprenavir, didanosine, efavirenz, nevirapine, and stavudine concentration in human plasma by MALDI-TOF/TOF.
Notari S, Mancone C, Alonzi T, et al  
J Chromatogr B Analyt Technol Biomed Life Sc
i. 2008 Jan 16
Abstract
 

Intra-Individual Variability in Efavirenz Plasma Concentrations Supports Therapeutic Drug Monitoring Based on Quarterly Sampling in the First Year of Therapy.
Pereira SA, Branco T, Caixas U, et al
Ther Drug Monit.
2008 Feb;30(1):60-66
Abstract
 
Efavirenz and Nevirapine in HIV-1 Infection : Is There a Role for Clinical Pharmacokinetic Monitoring?
Dahri K, Ensom MH. 
Clin Pharmacokinet.
2007;46(2):109-32.
Abstract
 
Development of a competitive immunoassay for efavirenz: Hapten design and validation studies.
Roucairol C, Azoulay S, Nevers MC, et al
Anal Chim Acta. 2
007 Apr 18;589(1):142-9.

Abstract

Efavirenz and nevirapine plasma levels in HIV-infected patients with hemophilia.
Martorell M, Lopez RM, Ribera E
Enferm Infecc Microbiol Clin. 2005 Jun;23(6):349-5

Abstract
 
Efavirenz Plasma Concentrations in HIV-Infected Patients: Inter- and Intraindividual Variability and Clinical Effects.
Stahle L, Moberg L, Svensson JO, Sonnerborg A.
Ther Drug Monit
. 2004 Jun;26(3):267-270.
Abstract


Economics
 

  Cost-effectiveness of CYP2B6 genotyping to optimize efavirenz dosing in HIV clinical practice.
Schackman BR, Haas DW, Park SS,et al
Pharmacogenomics
. 2015 Nov 26.
Abstract

Cost-Effectiveness of Nucleoside Reverse Transcriptase Inhibitor Pairs in Efavirenz-Based Regimens for Treatment-Naďve Adults with HIV Infection in the United States.
Brogan AJ, Talbird SE, Cohen C.
Value
Health
. 2011 Jul-Aug;14(5):657-64
Abstract

The cost-effectiveness analysis of initiating HIV/AIDS treatment with efavirenz-based regimens compared with nevirapine-based regimens in Thailand.
Maleewong U, Kulsomboon V, Teerawattananon Y.
J Med Assoc Thai. 2008 Jun;91 Suppl 2:S126-38.
Abstract


Efavirenz Main Page Main New/Newsworthy  Home Page      

Efavirenz Journal Citations